Answers are grounded in this paper and cite their sources.
Randomized trial compares bihormonal artificial pancreas effectiveness in glycemic control for patients post-pancreatectomy, indicating significant improvement.
Introduction and Objective: In patients undergoing total pancreatectomy (TP), adequate glycemic control is a major concern. Previously, a 7-day treatment with a bihormonal artificial pancreas (BIHAP), delivering both insulin and glucagon for fully closed-loop regulation, improved glycemic control. However, evidence on its long-term efficacy is lacking. Methods: This randomised open-label crossover trial compared BIHAP treatment with current diabetes care in adults after TP. Participants were randomised (1:1) to start with BIHAP or current diabetes care for 3 months, followed by a 3-month washout and crossover to the alternate treatment. The primary endpoint was the proportion of time spent in range (3.9 to 10.0 mmol/L; 70 to 180 mg/dL). The key secondary multiplicity-controlled endpoint was glycated hemoglobin (HbA1c). Results: Between April 26, 2023 and November 8, 2024, 34 patients were randomised. As predefined, those who completed both treatment periods were included in the primary analysis (n=20; 70% [n=14] male; median age, 65 years [IQR, 57 to 70]). During the standard care period, insulin was delivered by multiple daily injections in 16 patients and via insulin pump therapy in 4 patients; all patients used continuous glucose monitoring. The proportion of time spent in range was 24% higher (95% CI, 16 to 32; P<0.0001) with BIHAP compared with current diabetes care (mean [SD], 81% [7] vs 57% [19]). Glycated hemoglobin was 8 mmol/mol lower (IQR, 4 to 13; P=0.001) after BIHAP treatment (mean [SD], 56 mmol/mol [10] vs 64 mmol/mol [14]). Time below range (<3.9 mmol/L) was 0.9% (SD 0.8) with BIHAP versus 1.2% (SD 1.1) with current care (mean difference, -0.3; 95% CI, -0.8 to 0.3). Conclusion: In patients after TP, 3 months treatment with a fully closed-loop BIHAP significantly improved time in range and glycated hemoglobin levels compared with current diabetes care. These findings support the use of BIHAP in this population. Disclosure C. Leseman: None. J. De Vries: Consultant; Current; Gan & Lee Pharmaceuticals. Advisory Panel; Ended; Liom. Speaker's Bureau; Ended; Novo Nordisk A/S. Funding Dutch Cancer Society (14502); Inreda Diabetic B.V. provided medical devices under study (BIHAP 5, Inreda Diabetic B.
No takes yet. Share an insight, caveat, or question.
LESEMAN et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: